Cargando…
Molecular Tumor Board–Assisted Care in an Advanced Cancer Population: Results of a Phase II Clinical Trial
Multidisciplinary molecular tumor boards (MTBs) interpret next-generation sequencing reports and help oncologists determine best therapeutic options; however, there is a paucity of data regarding their clinical utility. The purpose of this study was to determine if MTB-directed therapy improves prog...
Autores principales: | Miller, Rachel W., Hutchcraft, Megan L., Weiss, Heidi L., Wu, Jianrong, Wang, Chi, Liu, Jinpeng, Jayswal, Rani, Buchanan, Mikayla, Anderson, Abigail, Allison, Derek B., El Khouli, Riham H., Patel, Reema A., Villano, John L., Arnold, Susanne M., Kolesar, Jill M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489195/ https://www.ncbi.nlm.nih.gov/pubmed/36103643 http://dx.doi.org/10.1200/PO.21.00524 |
Ejemplares similares
-
Molecular Tumor Board Review and Improved Overall Survival in Non–Small-Cell Lung Cancer
por: Huang, Bin, et al.
Publicado: (2021) -
MUTYH as an Emerging Predictive Biomarker in Ovarian Cancer
por: Hutchcraft, Megan L., et al.
Publicado: (2021) -
Neoadjuvant administration of hydroxychloroquine in a phase 1 clinical trial induced plasma Par-4 levels and apoptosis in diverse tumors
por: Wang, Peng, et al.
Publicado: (2018) -
Clinical Outcomes of Molecular Tumor Boards: A Systematic
Review
por: Larson, Kara L., et al.
Publicado: (2021) -
Real-World Evaluation of Universal Germline Screening for Cancer Treatment-Relevant Pharmacogenes
por: Hutchcraft, Megan L., et al.
Publicado: (2021)